Participants: ≥18 years, high myopia (≤−6.0 diopters or axial length of ≥26.5 mm), active subfoveal/juxtafoveal myopic CNV, BCVA 20/40-20/200
Intervention:
Group 1: Intravitreal Aflibercept 2mg at baseline, then q4weekly PRN if meet retreatment criteriae
Group 2: Sham q4weekly until week 20, then intravitreal Ablibercept at week 24 and q4weekly PRN if meet retreatment criteriae thereafter
Source Archive